BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, BBIO trades at $67.69 with a market cap of $12.79B and a P/E ratio of -18.26. BBIO moved +3.41% today. Year to date, BBIO is -7.08%; over the trailing twelve months it is +102.37%. Its 52-week range spans $21.72 to $84.94. Analyst consensus is strong buy with an average price target of $109.00. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes BBIO SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $67.69 |
| Market Cap | $12.79B |
| P/E Ratio | -18.26 |
| EPS | $-3.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $84.94 |
| 52-Week Low | $21.72 |
| Volume | 2.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $579.96M |
| Net Income | $-729.88M |
| Gross Margin | 95.13% |
17 analysts cover BBIO: 0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.00.